Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer - PubMed (original) (raw)

Review

Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer

Michael S Kinch et al. Clin Exp Metastasis. 2003.

Abstract

Cancer is a disease of aberrant signal transduction. The expression and function of intracellular signaling pathways are frequently subverted as cells progress towards a metastatic phenotype. In particular, tyrosine kinases initiate powerful signals that govern many different aspects of cell behavior. In Recent studies have demonstrated that the EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in aggressive tumor cells, and that these changes promote metastatic character. Herein, we provide an overview of our current understanding of EphA2, with emphasis upon the differential regulation of EphA2 expression and function. We also show that differential EphA2 expression and function may provide a unique opportunity for selective therapeutic targeting of EphA2 in metastatic disease.

PubMed Disclaimer

Similar articles

• EphA2-dependent molecular targeting therapy for malignant tumors.
  Biao-xue R, Xi-guang C, Shuan-ying Y, Wei L, Zong-juan M. Biao-xue R, et al. Curr Cancer Drug Targets. 2011 Nov;11(9):1082-97. doi: 10.2174/156800911798073050. Curr Cancer Drug Targets. 2011. PMID: 21933105 Review.
• Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
  Larsen AB, Stockhausen MT, Poulsen HS. Larsen AB, et al. Cell Signal. 2010 Apr;22(4):636-44. doi: 10.1016/j.cellsig.2009.11.018. Epub 2009 Dec 2. Cell Signal. 2010. PMID: 19948216
• Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
  Zhou Y, Sakurai H. Zhou Y, et al. Biol Pharm Bull. 2017;40(10):1616-1624. doi: 10.1248/bpb.b17-00446. Biol Pharm Bull. 2017. PMID: 28966234 Review.
• Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
  Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. Brantley-Sieders DM, et al. FASEB J. 2005 Nov;19(13):1884-6. doi: 10.1096/fj.05-4038fje. Epub 2005 Sep 15. FASEB J. 2005. PMID: 16166198

Cited by

• Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.
  Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Lema Tomé CM, et al. J Biol Chem. 2012 Apr 20;287(17):14012-22. doi: 10.1074/jbc.M111.311670. Epub 2012 Feb 23. J Biol Chem. 2012. PMID: 22362770 Free PMC article.
• Eph receptors and ephrins as targets for cancer therapy.
  Xi HQ, Wu XS, Wei B, Chen L. Xi HQ, et al. J Cell Mol Med. 2012 Dec;16(12):2894-909. doi: 10.1111/j.1582-4934.2012.01612.x. J Cell Mol Med. 2012. PMID: 22862837 Free PMC article. Review.
• Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2.
  Park SH, Park S, Kim DY, Pyo A, Kimura RH, Sathirachinda A, Choy HE, Min JJ, Gambhir SS, Hong Y. Park SH, et al. PLoS One. 2015 Jul 15;10(7):e0132976. doi: 10.1371/journal.pone.0132976. eCollection 2015. PLoS One. 2015. PMID: 26177208 Free PMC article.
• Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
  Chang Q, Jorgensen C, Pawson T, Hedley DW. Chang Q, et al. Br J Cancer. 2008 Oct 7;99(7):1074-82. doi: 10.1038/sj.bjc.6604676. Epub 2008 Sep 16. Br J Cancer. 2008. PMID: 18797457 Free PMC article.
• Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.
  Ansuini H, Meola A, Gunes Z, Paradisi V, Pezzanera M, Acali S, Santini C, Luzzago A, Mori F, Lazzaro D, Ciliberto G, Nicosia A, La Monica N, Vitelli A. Ansuini H, et al. J Oncol. 2009;2009:951917. doi: 10.1155/2009/951917. Epub 2010 Jan 14. J Oncol. 2009. PMID: 20130824 Free PMC article.

References

1. 1. Acta Anat (Basel). 1996;156(3):217-26 - PubMed
2. 1. Adv Cancer Res. 1999;76:1-20 - PubMed
3. 1. Growth Factors. 1993;9(3):243-52 - PubMed
4. 1. Curr Opin Cell Biol. 1997 Oct;9(5):608-15 - PubMed
5. 1. J Cell Biol. 1995 Jul;130(2):461-71 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal